Artivion Q4 revenue $97.3M (+4% YoY); FY2025 revenue guidance $420-435M

ARTIVION, INC.

2024-FY EPS reported -$0.32 revenue$388,537,000

Q4 revenue $97.3M (+4% GAAP, +3% constant currency); On-X, stent grafts, BioGlue each grew 8-10%.
Q4 net loss $(16.5)M ($0.39/share) vs loss $(4.0)M prior year; Adjusted EBITDA $17.6M (+15%).
FY2024 revenue $388.5M (+10% GAAP), net loss $(13.4)M vs $(30.7)M in 2023; Adjusted EBITDA $71.3M (+32%).
FDA granted Humanitarian Device Exemption for AMDS; second PMA module submitted; clinical data showed 50% mortality reduction.
FY2025 revenue guidance $420-435M (10-14% constant currency growth); adjusted EBITDA $84-91M (18-28% growth).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.